Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited
Key Takeaways
- The earliest sign metformin is working is a drop in fasting glucose, often visible within 1 to 2 weeks at therapeutic doses.
- A1C, the formal benchmark, drops by an average of 1.0 to 1.5 percentage points after 12 to 16 weeks at 1,500 to 2,000 mg per day (UKPDS 34, Lancet 1998).
- Mild GI side effects (loose stools, mild nausea, metallic taste) are the most common early signs the drug is in your system. They are not a sign it is "working" on glucose, just that you are absorbing it.
- Modest weight loss of 2 to 3 kg in 6 months is typical (DPP, NEJM 2002). Metformin is not primarily a weight-loss drug.
- If your fasting glucose has not dropped after 8 weeks at 1,500 mg or higher, your provider should consider a dose increase, an extended-release switch, or an additional medication.
Direct answer (40-60 words)
Metformin is working when your fasting glucose drops 10 to 30 mg/dL within 1 to 2 weeks, your post-meal glucose flattens, and your A1C falls by 1.0 to 1.5 percentage points by week 12 to 16. Modest weight loss, less hunger, and improved energy are common secondary signs.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- How metformin works (so the signs make sense)
- The eight signs metformin is working
- Timeline: when each sign shows up
- What if you feel nothing? Is the drug still working?
- Side effects vs signs of effect: do not confuse them
- When metformin is not working, and what to do
- Special populations: PCOS, prediabetes, and weight loss
- Lab values worth tracking
- FAQ
- Sources
- Footer disclaimers
How metformin works (so the signs make sense)
Metformin is a biguanide. It does three things, in rough order of importance:
- Reduces hepatic gluconeogenesis. Your liver makes less new glucose, especially overnight. This is why fasting glucose drops first.
- Improves insulin sensitivity in muscle. Your tissues take up more glucose for the same insulin signal. This flattens post-meal glucose curves.
- Modestly reduces intestinal glucose absorption and shifts the gut microbiome.
The cumulative effect is lower blood glucose with the same or lower insulin levels. That is the metabolic signature you are watching for.
The mechanism explains why the first signs are nighttime and morning glucose changes, not "feeling something" right after a dose. Metformin does not produce a sensation the way caffeine or insulin does.
The eight signs metformin is working
Sign 1: Fasting glucose drops within 1 to 2 weeks.
This is the earliest and most reliable sign. Therapeutic-dose metformin reduces fasting glucose by 20 to 40 mg/dL on average in patients with type 2 diabetes (UKPDS 34, Lancet 1998). If you have a glucometer or continuous glucose monitor, this is the easiest sign to see. Check fasting glucose every morning for the first 14 days and watch the trend.
Sign 2: Post-meal glucose spikes flatten.
After 2 to 4 weeks, post-meal glucose excursions become smaller. A meal that previously sent you to 220 mg/dL might cap at 170 mg/dL. The flattening is most visible after carbohydrate-heavy meals.
Sign 3: A1C drops at 12 to 16 weeks.
A1C is a 90-day average of glucose, so it lags. The expected drop on metformin monotherapy is 1.0 to 1.5 percentage points (e.g., 8.5% to 7.0%) at therapeutic doses. Smaller A1C drops (0.3 to 0.7) are common at 500 to 1,000 mg daily.
Sign 4: Mild weight loss of 2 to 3 kg over 6 months.
The Diabetes Prevention Program (DPP, NEJM 2002) showed an average 2.1 kg weight loss at 2.8 years on metformin 850 mg twice daily. Most of the loss happens in the first 6 months. Metformin is not Ozempic. Big weight loss on metformin alone is not the expected outcome.
Sign 5: Reduced appetite, especially for sweets.
Some patients report less interest in sweet foods within the first month. The mechanism likely involves the gut microbiome and modest GLP-1 elevation that metformin produces (Wu et al., Nat Med 2017). The effect is real but inconsistent. About 30 to 40% of patients notice it.
Sign 6: Improved energy, after the GI side effects settle.
In the first 1 to 2 weeks, metformin can make you feel worse (loose stools, mild nausea). After the gut adapts (typically by week 4), most patients notice steadier energy through the day, mostly because their glucose is no longer roller-coastering.
Sign 7: Triglycerides and LDL cholesterol modestly improve.
Metformin produces small reductions in triglycerides (about 10%) and LDL cholesterol (about 5 to 10%) over 12 to 24 weeks (UKPDS 34, Lancet 1998). HDL is largely unchanged. This is a secondary benefit, not the main reason metformin is prescribed.
Sign 8: For PCOS patients, more regular menstrual cycles.
In women with PCOS and insulin resistance, metformin restores ovulation in 30 to 50% of patients within 3 to 6 months (Lord et al., BMJ 2003). More regular cycles are a clinical marker that the insulin-sensitizing effect is doing what it should.
Timeline: when each sign shows up
| Sign | Typical onset | Magnitude |
|---|---|---|
| GI side effects (not a sign of efficacy) | Days 1 to 14 | Loose stools, mild nausea |
| Fasting glucose drop | Week 1 to 2 | 20 to 40 mg/dL |
| Post-meal glucose flattening | Week 2 to 4 | 30 to 60 mg/dL lower peaks |
| Reduced appetite for sweets | Week 2 to 8 | Variable, 30 to 40% of patients |
| Improved energy (post-GI adaptation) | Week 4 to 8 | Subjective |
| A1C drop | Week 12 to 16 | 1.0 to 1.5 points at full dose |
| Weight loss | Month 3 to 6 | 2 to 3 kg average |
| PCOS cycle regulation | Month 3 to 6 | 30 to 50% of patients |
| Triglyceride / LDL improvements | Month 3 to 6 | 5 to 10% |
If you are at 1,500 to 2,000 mg per day, hitting most of these markers in the first 12 weeks is the expected pattern. Hitting none of them is a reason to talk to your provider.
What if you feel nothing? Is the drug still working?
Often yes. Metformin does not produce a sensation. It quietly reduces hepatic glucose output overnight. Many patients on metformin feel exactly the same as before they started, while their fasting glucose drops 30 mg/dL.
The way to confirm whether metformin is working when you do not feel anything:
- Glucometer or CGM data. Compare your fasting glucose now to 2 weeks before starting.
- A1C at 12 weeks. If it has dropped, the drug is working.
- Lipid panel at 12 weeks. Modest improvements support the conclusion.
If you have no glucose data and no lab data, you have no way to know whether metformin is working. Get the labs. Patients who stop metformin because "I do not feel different" are usually stopping a drug that was working.
Side effects vs signs of effect: do not confuse them
This is a common mix-up. The presence or absence of side effects does not tell you whether metformin is reducing your glucose.
| Side effect | Means metformin is in your system | Does NOT mean it is working |
|---|---|---|
| Loose stools / diarrhea | Yes (40 to 60% of patients) | No |
| Mild nausea | Yes | No |
| Metallic taste | Yes | No |
| Decreased appetite | Sometimes a sign of effect | Sometimes just GI |
| Bloating, gas | Yes | No |
The mechanism of metformin GI side effects is partly direct gut irritation and partly serotonin release in the small intestine, both unrelated to glucose lowering (McCreight et al., Diabetologia 2016). You can have severe GI side effects with no glucose drop, and you can have a 50 mg/dL fasting glucose drop with zero side effects.
Switching to extended-release metformin (Glucophage XR, Fortamet) reduces GI side effects in 50 to 70% of intolerant patients while maintaining glucose-lowering effect (Blonde et al., Curr Med Res Opin 2004).
When metformin is not working, and what to do
Metformin is not working if, after 12 weeks at 1,500 to 2,000 mg per day:
- Your fasting glucose has not dropped at all
- Your A1C has not dropped at least 0.3 percentage points
- Your post-meal glucose excursions have not changed
Common reasons:
1. Dose is too low. Many patients are still at 500 mg daily after the titration period because the provider did not push the dose. The DPP data and UKPDS used 1,500 to 2,000 mg per day. Below that, expect smaller effects.
2. You are not taking it consistently. Metformin requires daily dosing. Missing 2 of 7 days a week roughly halves the effect.
3. Your insulin resistance is severe. In patients with longstanding type 2 diabetes, metformin alone may not be enough. A second agent (DPP-4 inhibitor, SGLT-2 inhibitor, or GLP-1 receptor agonist) is often added.
4. You have an alternative diagnosis. LADA (latent autoimmune diabetes of adults) and MODY do not respond well to metformin alone. Your provider may order C-peptide, GAD-65, or genetic testing if metformin is unexpectedly ineffective.
5. Lifestyle factors are overwhelming the drug. A continued high-carbohydrate intake, sedentary lifestyle, or untreated sleep apnea can blunt metformin's effect.
The next step is usually a provider conversation about: dose increase, switch to extended-release, addition of a second agent, or evaluation for an alternative diagnosis.
Internal link: For an overview of GLP-1 medications often added to metformin, see how GLP-1 receptor agonists work.
Special populations: PCOS, prediabetes, and weight loss
PCOS. Metformin is used off-label for PCOS in women with insulin resistance. The signs it is working include more regular menstrual cycles, lower fasting insulin, modest weight reduction, and improved ovulation. About 30 to 50% of PCOS patients ovulate spontaneously after 3 to 6 months on metformin (Lord et al., BMJ 2003).
Prediabetes. The DPP showed metformin reduces progression from prediabetes to type 2 diabetes by 31% over 2.8 years (DPP, NEJM 2002). The signs it is working in prediabetes are subtle: fasting glucose stays under 100 mg/dL, A1C stays under 5.7%, and weight is stable. Most prediabetic patients on metformin feel nothing.
Weight loss without diabetes. Metformin is not FDA-approved as a weight-loss drug. Off-label use produces 2 to 3 kg loss on average over 6 months, less than diet and exercise alone in motivated patients (Apolzan et al., Ann Intern Med 2019). If you are taking metformin for weight loss and are not also seeing glucose-related changes, the drug may not be doing much for you.
Internal link: For evidence-based weight-loss medication options, see comparing GLP-1 weight loss medications.
Lab values worth tracking
If you start metformin, ask for these labs at baseline and at 12 to 16 weeks:
| Lab | Baseline value | Goal at 12 weeks | What it tells you |
|---|---|---|---|
| Fasting glucose | Variable | Drop 20 to 40 mg/dL | Hepatic glucose output |
| A1C | Variable | Drop 1.0 to 1.5 points (full dose) | 90-day average glucose |
| Fasting insulin | Variable | Drop 20 to 40% | Insulin resistance |
| HOMA-IR | Variable | Drop 30 to 50% | Calculated insulin resistance |
| Lipid panel | Variable | TG and LDL down 5 to 10% | Secondary metabolic benefit |
| Vitamin B12 | Baseline only needed at 12 mo | Watch for deficiency | Long-term metformin can lower B12 |
| Creatinine / eGFR | Variable | Stable | Kidney function (metformin is renally cleared) |
Vitamin B12 deficiency develops in roughly 10 to 30% of patients on metformin for more than 5 years (de Jager et al., BMJ 2010). Annual B12 levels are a reasonable check after the first year.
FAQ
How long does it take for metformin to start working? Fasting glucose typically drops within 1 to 2 weeks at therapeutic doses. Post-meal glucose flattens by week 2 to 4. The full A1C effect takes 12 to 16 weeks because A1C is a 90-day average.
What is the most reliable sign metformin is working? A drop in fasting glucose, measured with a glucometer or CGM. It is the earliest, most direct, and most measurable sign. A1C confirmation at 12 weeks is the formal benchmark.
Will I feel different on metformin? Often, no. Metformin does not produce a sensation. The first 1 to 2 weeks may have GI side effects (loose stools, mild nausea), which most patients adapt to. After that, many patients feel exactly the same as before they started.
Does metformin help with weight loss? Modestly. Average weight loss is 2 to 3 kg over 6 months. Metformin is not a primary weight-loss drug. If your weight loss goal is more than 5 to 10 lbs, metformin alone is unlikely to deliver it.
What if my fasting glucose has not dropped after 4 weeks? Check the dose. If you are still at 500 mg daily, the dose is likely too low. Therapeutic effect typically requires 1,500 to 2,000 mg per day. Talk to your provider about a titration plan.
Does metformin help PCOS? Yes for many patients. About 30 to 50% of women with PCOS and insulin resistance ovulate spontaneously after 3 to 6 months on metformin. More regular cycles are a sign the drug is doing what it should.
Are GI side effects a sign metformin is working? No. Side effects mean the drug is in your system, not that it is lowering your glucose. You can have severe GI side effects with no glucose drop, or a major glucose drop with no side effects.
How do I know if I should switch to extended-release metformin? If GI side effects are intolerable past week 2 to 3, ask your provider about extended-release. Studies show 50 to 70% of intolerant patients tolerate the extended-release form while keeping the glucose-lowering benefit (Blonde et al., Curr Med Res Opin 2004).
Should I check my own glucose at home? For the first 4 to 8 weeks, yes if you can. Daily fasting glucose checks make it easy to see whether metformin is working. After A1C is at goal, less frequent checking is fine. CGMs make this much easier than fingersticks.
Can metformin stop working over time? Beta-cell function in type 2 diabetes declines slowly even with treatment. Metformin's effect may diminish after several years, requiring addition of a second medication. This is the natural history of the disease, not a failure of the drug.
Does metformin protect against heart disease? The UKPDS showed metformin reduces all-cause mortality and cardiovascular events in overweight type 2 diabetic patients by 30 to 40% (UKPDS 34, Lancet 1998). It is one of the few oral diabetes drugs with a clear cardiovascular outcome benefit.
Should I take metformin in the morning or evening? Immediate-release metformin is usually divided (e.g., 500 mg twice daily with meals). Extended-release is once daily, often with the evening meal. The timing matters less than the consistency. Take it at the same time every day.
Sources
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin (UKPDS 34). Lancet. 1998;352:854-865.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). N Engl J Med. 2002;346:393-403.
- Lord JM, et al. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-953.
- Wu H, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes. Nat Med. 2017;23:850-858.
- McCreight LJ, et al. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426-435.
- Blonde L, et al. Gastrointestinal tolerability of extended-release metformin tablets. Curr Med Res Opin. 2004;20:565-572.
- de Jager J, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency. BMJ. 2010;340:c2181.
- Apolzan JW, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170:682-690.
- Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes (ADA/EASD position statement). Diabetes Care. 2015;38:140-149.
- ADA Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
- Maruthur NM, et al. Diabetes medications as monotherapy or metformin-based combination therapy: systematic review. Ann Intern Med. 2016;164:740-751.
- Knowler WC, et al. 10-year follow-up of diabetes incidence and weight loss in the DPP Outcomes Study. Lancet. 2009;374:1677-1686.
- Hostalek U, et al. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75:1071-1094.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Glucophage, Glucophage XR, Fortamet, Glumetza, and Riomet are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →